These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 8120281

  • 1. Heterogeneity of phenotype in two siblings with adenosine deaminase deficiency.
    Umetsu DT, Schlossman CM, Ochs HD, Hershfield MS.
    J Allergy Clin Immunol; 1994 Feb; 93(2):543-50. PubMed ID: 8120281
    [Abstract] [Full Text] [Related]

  • 2. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles.
    Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS.
    Am J Hum Genet; 1998 Oct; 63(4):1049-59. PubMed ID: 9758612
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS, Chaffee S, Sorensen RU.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [Abstract] [Full Text] [Related]

  • 4. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [Abstract] [Full Text] [Related]

  • 5. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D, Gur Cetinkaya P, Karaatmaca B, Esenboga S, Tan C, Yılmaz T, Gümüş E, Barış S, Kuşkonmaz B, Ozgur TT, Bali P, Santisteban I, Orhan D, Yüce A, Cetinkaya D, Boztug K, Hershfield M, Sanal O, Tezcan İ.
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [Abstract] [Full Text] [Related]

  • 6. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
    Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, Matsumoto S, Kotani H, McGarrity GJ, Blaese RM, Sakiyama Y.
    Blood; 1998 Jan 01; 91(1):30-6. PubMed ID: 9414266
    [Abstract] [Full Text] [Related]

  • 7. Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.
    Arredondo-Vega FX, Santisteban I, Kelly S, Schlossman CM, Umetsu DT, Hershfield MS.
    Am J Hum Genet; 1994 May 01; 54(5):820-30. PubMed ID: 8178821
    [Abstract] [Full Text] [Related]

  • 8. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS.
    Immunodeficiency; 1993 May 01; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities.
    Blackburn MR, Aldrich M, Volmer JB, Chen W, Zhong H, Kelly S, Hershfield MS, Datta SK, Kellems RE.
    J Biol Chem; 2000 Oct 13; 275(41):32114-21. PubMed ID: 10908569
    [Abstract] [Full Text] [Related]

  • 12. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
    Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF.
    Science; 1995 Oct 20; 270(5235):475-80. PubMed ID: 7570001
    [Abstract] [Full Text] [Related]

  • 13. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K, Hershfield MS, Bastian J, Kohn D, Sender L, Parkman R, Lenarsky C.
    J Clin Invest; 1993 Aug 20; 92(2):596-602. PubMed ID: 8349799
    [Abstract] [Full Text] [Related]

  • 14. Adenosine deaminase (ADA) deficiency as the unexpected cause of CD4+ T-lymphocytopenia in two HIV-negative adult female siblings.
    Fairbanks LD, Simmonds HA, Webster AD, Shovlin CL, Hughes JM.
    Adv Exp Med Biol; 1994 Aug 20; 370():471-4. PubMed ID: 7660952
    [No Abstract] [Full Text] [Related]

  • 15. Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.
    Liu P, Santisteban I, Burroughs LM, Ochs HD, Torgerson TR, Hershfield MS, Rawlings DJ, Scharenberg AM.
    Clin Immunol; 2009 Feb 20; 130(2):162-74. PubMed ID: 18952502
    [Abstract] [Full Text] [Related]

  • 16. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
    Bory C, Boulieu R, Souillet G, Chantin C, Guibaud P, Hershfield MS.
    Adv Exp Med Biol; 1991 Feb 20; 309A():173-6. PubMed ID: 1789201
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
    Hershfield MS.
    Hum Mutat; 1995 Feb 20; 5(2):107-12. PubMed ID: 7749407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.